Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Sharing Miracles Television Program to Feature Emmy Award-Winning Actor Joey Pantoliano
- To: NATIONAL EDITORS Contact: Kate Michael of PhRMA, +1-202-835-3460 WASHINGTON, April 2, 2008 /PRNewswire-USNewswire/ -- This month, Sharing Miracles - a 30-minute public affairs television program that tells the compelling and inspirational stories of real patients - will feature Joey Pantoliano, an Emmy Award-winning actor, writer and producer who...
- Research articles 2008-04-02
- PhRMA lobbying spend soared by 25% in 2007
- PHRMA SPENT more than $22 million lobbying the federal government last year-nearly a 25% increase from the amount spent in 2006, disclosure records filed by the group in February show. According to the records, PhRMA spent $12 million in the second half of 2007 lobbying against efforts, including a bill...
- Research articles 2008-04-01
- 'Sharing Miracles' Television Program to Feature Mountain Climber and Cancer Survivor Sean Swarner
- To: RADIO-TELEVISION EDITORS Contact: Kate Michael of the Pharmaceutical Research and Manufacturers of America, +1-202-835-3460 WASHINGTON, March 6 /PRNewswire-USNewswire/ -- This month, Sharing Miracles-- a 30-minute public affairs television program that tells the compelling and inspirational stories of real patients -- will feature Sean Swarner, a two-time cancer survivor...
- Research articles 2008-03-06
- New Study Reveals Generic Drugs Continue Entering Market as Competition from Authorized Generics Increases
- To: HEALTH/MEDICAL EDITORSContact: Jennifer Page of PhRMA, +1-202-835-3460 WASHINGTON, April 19 /PRNewswire-USNewswire/ -- According to a new study by researchers at the Massachusetts Institute of Technology's MIT School of Management and Analysis Group Inc., there is no evidence that the recent increase in prevalence of authorized generics has resulted in...
- Research articles 2007-04-19
- The Rudy You Don't Know:
- To: POLITICAL EDITORSContact: Stacie Paxton or Mark Paustenbach, +1-202-863-8148, both of the Democratic National Committee WASHINGTON, March 15 /PRNewswire-USNewswire/ -- Once again, Rudy Giuliani's business interests and his refusal to divulge a full list of all his businesses' clients are creating a problem for the GOP Presidential hopeful. This is...
- Research articles 2007-03-15
- Democratic National Committee: Rudy's Reluctant Candidacy Exposes Controversial Business Dealings
- To: POLITICAL EDITORSContact: Dag Vega or Karen Finney, +1-202-862-8148, both of the Democratic National Committee WASHINGTON, Feb. 5 /PRNewswire-USNewswire/ -- The following was released today by the Democratic National Committee: After months of giving non-committal responses to questions about a possible presidential run, Rudy Giuliani today filed his "statement...
- Research articles 2007-02-05
- HOUSE OF HEARINGS
- With the Democrats set to take control of Congress, the new guard of committee leadership presents a mixed-to-bleak picture for pharma industry interests. Hearings, hearings and more hearings on the dastardly doings of the pharmaceutical industry will be the order of the day for a Democratic Congress, Washington...
- Research articles 2006-12-01
- AARP keeps finger on Rx prices
- WASHINGTON -- Wholesale drug prices are rising faster than the rate of inflation, according to a report from AARP. "Prices for brand name drugs have jumped 40% on average over the past six years, compared with inflation of only 17%," says John Rother, AARP director of policy and strategy....
- Research articles 2006-04-24
- Drug-firm group prescribes Tauzin.(Billy Tauzin )(Brief Article)
- WASHINGTON -- Rep. Billy Tauzin (R-La.)--who turned down the role of Hollywood's top Washington, D.C., lobbyist--last Wednesday was named president and CEO of the Pharmaceutical Research and Manufacturers of America PhRMA, a group that represents such drug giants as Merck & Co. Inc. and Abbott Laboratories....
- Research articles 2004-12-20
- Drug-Firm Group Prescribes Tauzin (Multichannel News)
- Washington-- Rep. Billy Tauzin (R-La.) -- who turned down the role of Hollywood's top Washington, D.C., lobbyist -- last Wednesday was named president and CEO of the Pharmaceutical Research and Manufacturers of America PhRMA, a group that represents such drug giants as Merck & Co. Inc. and Abbott Laboratories. ...
- Research articles 2004-12-20
- PhRMA calls for 'critical path' support
- PHARMACEUTICAL Research and Manufacturers of America PhRMA says one of the most important things the Department of Health and Human Services could do to further medical innovation is to fully support and adequately fund PDA's critical path initiative PhRMA said that despite significant success in the last decade in developing...
- Research articles 2004-11-01
- Study Says Drug Imports May Not Hurt Profits.
- By Christopher Rowland, The Boston Globe Knight Ridder/Tribune Business News Apr. 15--Boston University researchers say they have found a big hole in the pharmaceutical industry's argument that cheap prescription imports from Canada would hurt profits that fuel critical research for new...
- Research articles 2004-04-15
- Springfield, Mass., Mayor Exits after Making Dent in Drug Giants' Profits.
- By Christopher Rowland, The Boston Globe Knight Ridder/Tribune Business News Jan. 3--Mayor Michael Albano cleaned out his desk at Springfield City Hall yesterday in preparation for giving up his office on Monday, but even as he loaded boxes with memorabilia and accepted...
- Research articles 2004-01-03
- Drug companies up the ante in battle against price control
- WASHINGTON -- Lobbyists for the drug industry are stepping up spending to influence Congress, the states and even foreign governments as the debate intensifies over how to provide prescription drug benefits to the elderly, industry executives say. Confidential budget documents from the leading pharmaceutical trade group show...
- Research articles 2003-06-01
- Medicaid and the unconstitutional dimensions of prior authorization.(Case Note)
- TABLE OF CONTENTS INTRODUCTION I. THE STRONG MEDICINE OF PREEMPTION A. A Purposive Framework: The Search for Intent ...
- Research articles 2002-11-01
- Legislation Supporting Generic Drugs Appears Stalled in House.
- By Lewis Krauskopf, The Record, Hackensack, N.J. Knight Ridder/Tribune Business News Oct. 4--Backers of a bill that would ease access to generic drugs appear to have lost -- to Montel Williams, Leeza Gibbons, and the pharmaceutical industry. A celebrity-fueled...
- Research articles 2002-10-04
- High Court To Weigh Many Business Issues.
- Byline:Dean Scott The U.S. Supreme Court will weigh in on an unusually large number of legal questions important to business during its upcoming term. The justices will consider cases involving copyright and trademark protections, punitive damage awards and state attempts to control runaway...
- Research articles 2002-09-27
- 'The profits that kill'
- In a recent major series that ran over four days titled "Dying For Drugs", the British daily, The Guardian, exposed how the West's pharmaceutical giants are capitalising on "intellectual property agreements" and "making too much money for the West". They are even selling the new anti-retroviral Aids drugs at a...
- Research articles 2001-04-01
- Caution: Politics ahead
- As a regular contributor to MM&M, Carl Seiden usually reviews individual companies. This time he tackles a more challenging topic: how the political environment is likely to impact the pharmaceutical industry. As his analysis shows, the outcome of next month's election is only one of the uncertainties management has to...
- Research articles 2000-10-01
- AIDS Drugs for Africa.
- The author examine the US reversal on attempts to block AIDS drugs to Africa. Topics include AIDS activists, patent protection, and the cost of drugs. Grassroots Pressure Overcomes U.S.-Industry "Full Court Press" to Block South Africa's Affordable Medicine Program SOMETIMES, THE MULTINATIONALS LOSE. ...
- Research articles 1999-09-01
- << Previous
- page 1 of 3
- Next >>
Refining Tags
- FDA (16 results)
- Pharmaceutical Company (12 results)
- Healthcare (11 results)
- U.S. Congress (9 results)
- Strategy (8 results)
- Benefits (6 results)
- U.S. Senate (6 results)
- Health Care (5 results)
- Patient (5 results)
- Software (4 results)
- Jim Edwards (4 results)
- U.S. Department of Health and Human Services (4 results)
- R&D (4 results)
- Lobbyist (4 results)
- Medicare (3 results)
- Vertical Industries (3 results)
- Maine (3 results)
- Human Resources (3 results)
- manufacturer (3 results)
- Advertisement (3 results)
- Marketing (3 results)
- prescription drug (3 results)
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
